In this special Press Pass episode of the Making Medicine Podcast, John Stanford welcomes Nyah Phengsitthy of Bloomberg Law to break down the latest shifts in drug pricing, FDA policy, and the unpredictable pace of the Trump administration. They explore the Medicare drug price negotiation program, new FDA leadership under Dr. Makary, and the industry’s reaction to rapidly changing executive orders. Nyah also shares her approach to filtering meaningful policy changes from political noise. Plus, they dive into how upcoming guidance may reshape the role of physicians in Part B drug distribution and what that means for innovation in medicine. How should industry leaders respond to policy announced via social media posts? Will the new FDA leadership redefine efficiency and access in drug approval? What worries you most (or excites you) about the future of drug pricing policy?

📱If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 

Timestamps:
0:00 There's a lot going on
0:36 Welcome to Making Medicine
1:00 Introducing Nyah Phengsitthy and Press Pass
1:40 Top trends in drug policy under Trump
2:52 Uncertainty and industry response
3:57 How Nyah filters news vs. noise
5:29 A changing FDA and its new direction 
6:49 Stakeholder engagement and Makary’s listening tour
7:51 Industry frustration over vague policy
9:00 Medicare drug negotiation: Trump’s first take
10:47 Fixed dose combos and Orphan Cures Act in new guidance
11:50 Part B dynamics and physician involvement
12:56 Listening sessions and future guidance
13:19 Final thoughts and wrap-up